Skip to main content
Fig. 2 | Journal of Neurodevelopmental Disorders

Fig. 2

From: Is dopamine transporter-mediated dopaminergic signaling in the retina a noninvasive biomarker for attention-deficit/ hyperactivity disorder? A study in a novel dopamine transporter variant Val559 transgenic mouse model

Fig. 2

The DAT Val559 homozygous mutation affects light-adapted retinal function via dopaminergic signaling in male mice. a, b, and c Light-adapted (photopic) ERG b-wave amplitudes (μV) plotted as a function of light adaption time (minutes) in all groups. a Mice carrying homozygous Val559 mutation of DAT (HOM: open circles) have significantly higher photopic b-wave amplitudes compared to WT (filled triangles) and HET (filled circles; F (2,256) = 26.98, ***P < 0.001, two-way ANOVA, n = 9–14 mice). b Injection of D1/D4 receptor agonists (SKF38393 and PD168077, 1 mg/kg, respectively) elevated the photopic ERG in WT animals (open circles) compared with untreated group (filled circles; F (1,136) = 4.124, *P = 0.044, two-way ANOVA, n = 5–14 mice). c Injection of D4 receptor-selective antagonist L-745,870 (1 mg/kg) significantly reduced the response amplitude of DAT HOM (open circles; F (1,104) = 82.06, ***P < 0.001, two-way ANOVA, n = 6–9 mice). All data are represented as means ± SEM

Back to article page